Posted innews OB/GYN & Women’s Health Oncology
Innovative Phase II Trial of Carboplatin, Paclitaxel, and Pembrolizumab with HIPEC and Olaparib Maintenance in Advanced Epithelial Ovarian Cancer
This phase II study evaluates pembrolizumab combined with carboplatin/paclitaxel and HIPEC in neoadjuvant therapy, followed by pembrolizumab maintenance with or without olaparib in advanced stage III/IV epithelial ovarian cancer patients.
